Dave Duplay sits down with John L. Lehr, President & CEO of the Parkinson's Foundation, to talk about the challenges faced by those affected by Parkinson's disease, and what the Parkinson's Foundation is doing to help raise awareness and find a cure.
Health360: HealthTalk: John L. Lehr | Parkinson's Awareness Month
CEO John L. Lehr discussed the Foundation’s work in this TV interview at Moving Day® Twin Cities held last weekend.
The YMCA of Metro Atlanta has been given a $20,000 grant from the Foundation to expand group fitness classes, award scholarships and offer free memberships to people with PD.
A new trial suggests that the injectable drug apomorphine (Apokyn) can significantly shorten “off” times between levodopa dosages. Parkinson’s Foundation National Medical Director Dr. Michael S. Okun is quoted.
Parkinson Foundation CEO John L. Lehr gives discusses a world without Parkinson's and how he intends to bring his vision to fruition to better the lives of those affected by Parkinson's.
NPF division’s Western New York chapter is celebrating Parkinson’s Awareness Month through distributing blue light bulbs, sponsoring wear blue day and hosting its annual wine tasting.
When Gary Smith was diagnosed with PD he began playing golfing at Topgolf®. He noticed that his stiffness lessened and his health improved. In honor of Gary and World Parkinson's Day, Topgolf donated $10,000 to the Parkinson's Foundation.
John L. Lehr, CEO of the Parkinson's Foundation, and Allison Willis, M.D., M.S., a Parkinson’s disease specialist and assistant professor of neurology and biostatistics in epidemiology at the University of Pennsylvania, about a new initiative to close the gap in sex-based disparities.
Leading PD non-profits share their Awareness Month plans and what they want others to know about Parkinson’s. Leilani Pearl, the Foundation’s vice president of marketing and communications, is quoted.
Parkinson’s Foundation CEO John Lehr is quoted in regards to the FDA’s recent approval to allow 23andMe to market genetic health risk tests.
23andMe announced it’s recent FDA authorization to market its Personal Genome Service Genetic Health Risk (GHR) tests for 10 hereditary disorders. Parkinson’s Foundation CEO John Lehr is quoted.